International Society for Quality of Life Research commentary on the draft European Medicines Agency reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies

Derek Kyte, Bryce B. Reeve, Fabio Efficace, Kirstie Haywood, Rebecca Mercieca-Bebber, Madeleine T. King, Josephine M. Norquist, William R. Lenderking, Claire Snyder, Lena Ring, Galina Velikova, Melanie Calvert

Research output: Contribution to journalArticle

Abstract

In 2014, the European Medicines Agency (EMA) released for comment a draft reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies. A twelve-member International Society for Quality of Life Research (ISOQOL) taskforce was convened to coordinate the ISOQOL response. Twenty-one ISOQOL members provided detailed comments and suggestions on the paper: 81 % from academia and 19 % from industry. Taskforce members consolidated and further refined these comments and shared the recommendations with the wider ISOQOL membership. A final response was submitted to the EMA in November 2014. The impending publication of the EMA reflection paper presents a valuable opportunity for ISOQOL to comment on the current direction of EMA PRO guidance and strategy. The EMA paper, although focused on cancer, could serve as a model for using PROs in other conditions, as it provides a useful update surrounding some of the design issues common to all trial research including PRO endpoints. However, we believe there are a number of additional areas in need of greater consideration. The purpose of this commentary is therefore to highlight the strengths of this timely and potentially useful document, but also to outline areas that may warrant further discussion.

Original languageEnglish (US)
Pages (from-to)359-362
Number of pages4
JournalQuality of Life Research
Volume25
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Quality of Life
Research
Publications
Patient Reported Outcome Measures
Industry
Neoplasms

Keywords

  • European Medicines Agency
  • Health-related quality of life
  • HRQL
  • International Society for Quality of Life Research
  • Oncology
  • Patient-reported outcomes
  • PROs

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

International Society for Quality of Life Research commentary on the draft European Medicines Agency reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies. / Kyte, Derek; Reeve, Bryce B.; Efficace, Fabio; Haywood, Kirstie; Mercieca-Bebber, Rebecca; King, Madeleine T.; Norquist, Josephine M.; Lenderking, William R.; Snyder, Claire; Ring, Lena; Velikova, Galina; Calvert, Melanie.

In: Quality of Life Research, Vol. 25, No. 2, 01.02.2016, p. 359-362.

Research output: Contribution to journalArticle

Kyte, D, Reeve, BB, Efficace, F, Haywood, K, Mercieca-Bebber, R, King, MT, Norquist, JM, Lenderking, WR, Snyder, C, Ring, L, Velikova, G & Calvert, M 2016, 'International Society for Quality of Life Research commentary on the draft European Medicines Agency reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies', Quality of Life Research, vol. 25, no. 2, pp. 359-362. https://doi.org/10.1007/s11136-015-1099-z
Kyte, Derek ; Reeve, Bryce B. ; Efficace, Fabio ; Haywood, Kirstie ; Mercieca-Bebber, Rebecca ; King, Madeleine T. ; Norquist, Josephine M. ; Lenderking, William R. ; Snyder, Claire ; Ring, Lena ; Velikova, Galina ; Calvert, Melanie. / International Society for Quality of Life Research commentary on the draft European Medicines Agency reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies. In: Quality of Life Research. 2016 ; Vol. 25, No. 2. pp. 359-362.
@article{a8c843fbb2e9414f8960295d24fe8d39,
title = "International Society for Quality of Life Research commentary on the draft European Medicines Agency reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies",
abstract = "In 2014, the European Medicines Agency (EMA) released for comment a draft reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies. A twelve-member International Society for Quality of Life Research (ISOQOL) taskforce was convened to coordinate the ISOQOL response. Twenty-one ISOQOL members provided detailed comments and suggestions on the paper: 81 {\%} from academia and 19 {\%} from industry. Taskforce members consolidated and further refined these comments and shared the recommendations with the wider ISOQOL membership. A final response was submitted to the EMA in November 2014. The impending publication of the EMA reflection paper presents a valuable opportunity for ISOQOL to comment on the current direction of EMA PRO guidance and strategy. The EMA paper, although focused on cancer, could serve as a model for using PROs in other conditions, as it provides a useful update surrounding some of the design issues common to all trial research including PRO endpoints. However, we believe there are a number of additional areas in need of greater consideration. The purpose of this commentary is therefore to highlight the strengths of this timely and potentially useful document, but also to outline areas that may warrant further discussion.",
keywords = "European Medicines Agency, Health-related quality of life, HRQL, International Society for Quality of Life Research, Oncology, Patient-reported outcomes, PROs",
author = "Derek Kyte and Reeve, {Bryce B.} and Fabio Efficace and Kirstie Haywood and Rebecca Mercieca-Bebber and King, {Madeleine T.} and Norquist, {Josephine M.} and Lenderking, {William R.} and Claire Snyder and Lena Ring and Galina Velikova and Melanie Calvert",
year = "2016",
month = "2",
day = "1",
doi = "10.1007/s11136-015-1099-z",
language = "English (US)",
volume = "25",
pages = "359--362",
journal = "Quality of Life Research",
issn = "0962-9343",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - International Society for Quality of Life Research commentary on the draft European Medicines Agency reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies

AU - Kyte, Derek

AU - Reeve, Bryce B.

AU - Efficace, Fabio

AU - Haywood, Kirstie

AU - Mercieca-Bebber, Rebecca

AU - King, Madeleine T.

AU - Norquist, Josephine M.

AU - Lenderking, William R.

AU - Snyder, Claire

AU - Ring, Lena

AU - Velikova, Galina

AU - Calvert, Melanie

PY - 2016/2/1

Y1 - 2016/2/1

N2 - In 2014, the European Medicines Agency (EMA) released for comment a draft reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies. A twelve-member International Society for Quality of Life Research (ISOQOL) taskforce was convened to coordinate the ISOQOL response. Twenty-one ISOQOL members provided detailed comments and suggestions on the paper: 81 % from academia and 19 % from industry. Taskforce members consolidated and further refined these comments and shared the recommendations with the wider ISOQOL membership. A final response was submitted to the EMA in November 2014. The impending publication of the EMA reflection paper presents a valuable opportunity for ISOQOL to comment on the current direction of EMA PRO guidance and strategy. The EMA paper, although focused on cancer, could serve as a model for using PROs in other conditions, as it provides a useful update surrounding some of the design issues common to all trial research including PRO endpoints. However, we believe there are a number of additional areas in need of greater consideration. The purpose of this commentary is therefore to highlight the strengths of this timely and potentially useful document, but also to outline areas that may warrant further discussion.

AB - In 2014, the European Medicines Agency (EMA) released for comment a draft reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies. A twelve-member International Society for Quality of Life Research (ISOQOL) taskforce was convened to coordinate the ISOQOL response. Twenty-one ISOQOL members provided detailed comments and suggestions on the paper: 81 % from academia and 19 % from industry. Taskforce members consolidated and further refined these comments and shared the recommendations with the wider ISOQOL membership. A final response was submitted to the EMA in November 2014. The impending publication of the EMA reflection paper presents a valuable opportunity for ISOQOL to comment on the current direction of EMA PRO guidance and strategy. The EMA paper, although focused on cancer, could serve as a model for using PROs in other conditions, as it provides a useful update surrounding some of the design issues common to all trial research including PRO endpoints. However, we believe there are a number of additional areas in need of greater consideration. The purpose of this commentary is therefore to highlight the strengths of this timely and potentially useful document, but also to outline areas that may warrant further discussion.

KW - European Medicines Agency

KW - Health-related quality of life

KW - HRQL

KW - International Society for Quality of Life Research

KW - Oncology

KW - Patient-reported outcomes

KW - PROs

UR - http://www.scopus.com/inward/record.url?scp=84955372111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955372111&partnerID=8YFLogxK

U2 - 10.1007/s11136-015-1099-z

DO - 10.1007/s11136-015-1099-z

M3 - Article

VL - 25

SP - 359

EP - 362

JO - Quality of Life Research

JF - Quality of Life Research

SN - 0962-9343

IS - 2

ER -